We have previously shown that suppressing TKTL1 expression in glioma cells increases ROS under hypoxic conditions and antagonizes the protection against hypoxia-induced cell death conferred by TP53-induced glycolysis and apoptosis regulator (TIGAR) [7]. Here, TKTL1 is linked to central nervous system cancer.